九典制药(300705) - 九典制药投资者关系管理信息

Group 1: Sales Performance - The total sales revenue of the company's patch products for the first three quarters reached 1.169 billion CNY, representing a year-on-year growth of 6.46% [2] - Sales volume increased by 60.63% year-on-year [2] - In the third quarter, the total sales revenue of patch products was 462 million CNY, with a year-on-year growth of 15.57% [2] Group 2: Product Development and Market Expansion - The company has developed over 800 first-level hospitals and nearly 2,000 terminal hospitals, focusing on increasing hospital sales [2] - The company plans to launch the anti-inflammatory and analgesic patch this month, with OTC channels as the primary sales strategy [3] - Future product approvals include indomethacin gel patch and flurbiprofen gel patch expected in 2025, and several other topical formulations anticipated in 2026 [3] Group 3: Procurement and Market Strategy - The company is currently focusing on expanding its market presence in regions where provincial procurement has been executed [1] - The company expects to participate in the first round of national procurement with several generic drugs, which will support future profit growth [2] - Potential products for future procurement include sitagliptin tablets, simethicone emulsion, and others [3]